ResearcherUniversity of WrocławActive in the last 2 years
Magdalena Zaremba-Czogalla
Matched on ORCID iD 0000-0003-0182-7299; OpenAlex author ID A5025262865.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 5
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper
Papers 7
- Metabolic Collapse in Pancreatic Cancer via Combined Inhibition of Lactate Export and Thioredoxin Reductase Co-author DOI 10.1101/2025.07.09.663998↗
- The conjugates of 5'-deoxy-5-fluorocytidine and hydroxycinnamic acids - synthesis, anti-pancreatic cancer activity and molecular docking studies. Co-author DOI 10.1039/d4ra01683a↗
- The Conjugates of Indolo[2,3-b]quinoline as Anti-Pancreatic Cancer Agents: Design, Synthesis, Molecular Docking and Biological Evaluations. Co-author DOI 10.3390/ijms25052573↗
- Novel Liposomal Formulation of Baicalein for the Treatment of Pancreatic Ductal Adenocarcinoma: Design, Characterization, and Evaluation. Co-author DOI 10.3390/pharmaceutics15010179↗
- Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells. Co-author DOI 10.3390/ijms23105536↗
- Evaluation of the In Vitro Cytotoxic Activity of Ursolic Acid PLGA Nanoparticles against Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/ma14174917↗
- Evaluation of the In Vitro Cytotoxic Activity of Caffeic Acid Derivatives and Liposomal Formulation against Pancreatic Cancer Cell Lines. First author DOI 10.3390/ma13245813↗
Closest collaborators
The 5 strongest of 5 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Jerzy Gubernator · 6 shared papers, 2020–2025
- Paper Metabolic Collapse in Pancreatic Cancer via Combined Inhibition of Lactate Export and Thioredoxin Reductase DOI 10.1101/2025.07.09.663998↗
- Paper The conjugates of 5'-deoxy-5-fluorocytidine and hydroxycinnamic acids - synthesis, anti-pancreatic cancer activity and … DOI 10.1039/d4ra01683a↗
- Paper Novel Liposomal Formulation of Baicalein for the Treatment of Pancreatic Ductal Adenocarcinoma: Design, Characterizatio… DOI 10.3390/pharmaceutics15010179↗
- Adrianna Zygmunt · 4 shared papers, 2021–2025
- Paper Metabolic Collapse in Pancreatic Cancer via Combined Inhibition of Lactate Export and Thioredoxin Reductase DOI 10.1101/2025.07.09.663998↗
- Paper Novel Liposomal Formulation of Baicalein for the Treatment of Pancreatic Ductal Adenocarcinoma: Design, Characterizatio… DOI 10.3390/pharmaceutics15010179↗
- Paper Evaluation of the In Vitro Cytotoxic Activity of Ursolic Acid PLGA Nanoparticles against Pancreatic Ductal Adenocarcino… DOI 10.3390/ma14174917↗
- Adam Markowski · 4 shared papers, 2021–2025
- Paper Metabolic Collapse in Pancreatic Cancer via Combined Inhibition of Lactate Export and Thioredoxin Reductase DOI 10.1101/2025.07.09.663998↗
- Paper Novel Liposomal Formulation of Baicalein for the Treatment of Pancreatic Ductal Adenocarcinoma: Design, Characterizatio… DOI 10.3390/pharmaceutics15010179↗
- Paper Evaluation of the In Vitro Cytotoxic Activity of Ursolic Acid PLGA Nanoparticles against Pancreatic Ductal Adenocarcino… DOI 10.3390/ma14174917↗
- Marcin Cybulski · 3 shared papers, 2020–2024
- Paper The Conjugates of Indolo[2,3-b]quinoline as Anti-Pancreatic Cancer Agents: Design, Synthesis, Molecular Docking and Bio… DOI 10.3390/ijms25052573↗
- Paper The conjugates of 5'-deoxy-5-fluorocytidine and hydroxycinnamic acids - synthesis, anti-pancreatic cancer activity and … DOI 10.1039/d4ra01683a↗
- Paper Evaluation of the In Vitro Cytotoxic Activity of Caffeic Acid Derivatives and Liposomal Formulation against Pancreatic … DOI 10.3390/ma13245813↗
- Olga Michalak · 2 shared papers, 2024
- Paper The Conjugates of Indolo[2,3-b]quinoline as Anti-Pancreatic Cancer Agents: Design, Synthesis, Molecular Docking and Bio… DOI 10.3390/ijms25052573↗
- Paper The conjugates of 5'-deoxy-5-fluorocytidine and hydroxycinnamic acids - synthesis, anti-pancreatic cancer activity and … DOI 10.1039/d4ra01683a↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.